---
document_datetime: 2025-12-18 11:54:57
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/saphnelo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: saphnelo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.6703355
conversion_datetime: 2026-02-01 20:44:59.649534
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Saphnelo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                    |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------|
| X/0023               | Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration Annex I_2.(c) Change or addition of a new strength/potency | 16/10/2025                          | 12/12/2025                                  | SmPC, Labelling and PL           | Please refer to the scientific discussion: Saphnelo EMEA/H/C/004975/X/0023 |
| PSUSA/10980          | Periodic Safety Update EU Single assessment -                                                                                                                                              | 13/02/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                          |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| /202407             | anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0022/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                         | 13/12/2024 | n/a |                                   |
| II/0020             | Submission of the final report from the NA√èVE study D3461C00023/ESR-20-21053, listed as a category 3 study in the RMP. This study is a phase I, non- randomised, multi-centre, open-label, parallel group study to evaluate the potential impact of anifrolumab administered intravenously (IV) on the effectiveness of immune responses to seasonal influenza vaccination in women or men between the ages of 18 and 70 years with active moderate to severe manifestations of SLE. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 07/11/2024 | n/a |                                   |
| PSUSA/10980 /202401 | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/09/2024 | n/a | PRAC Recommendation - maintenance |
| IB/0019             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/08/2024 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10980 /202307   | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/03/2024   | 16/05/2024   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10980/202307.   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/03/2024   | 16/05/2024   | SmPC and PL   |                                                                                                                                              |
| IA/0014               | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/01/2024   | 16/05/2024   | SmPC          |                                                                                                                                              |
| IB/0012/G             | This was an application for a group of variations. B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 24/10/2023   | n/a          |               |                                                                                                                                              |
| IB/0011               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/09/2023   | n/a          |               |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007             | Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on final results from study D3461C00009 listed as an additional pharmacovigilance activity in the RMP; this is a multicentre, randomised, double- blind, placebo-controlled Phase III extension study to characterise the long-term safety and tolerability of anifrolumab in adult subjects with active systemic lupus erythematosus. In addition, the MAH took the opportunity to implement minor changes to sections 4.2 and 6.6 of the SmPC and to the Package Leaflet. In addition, the MAH took the opportunity to update the list of local representatives in the Netherlands in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/09/2023 | 16/05/2024 | SmPC and PL     | Patients who completed D3461C00004 [study 04] and study D3461C00005 [study 05] (feeder trials) through Week 52 were eligible to continue on treatment in a randomised, double-blind, placebo-controlled, 3-year Long Term Extension (study D3461C00009). Following long-term observations, the clearance of anifrolumab was found to be stable in years 2 through 4 on treatment. Long-term efficacy was evaluated in patients who received anifrolumab 300 mg or placebo in a feeder trial and continued to receive the same treatment in the LTE (anifrolumab N=257; placebo N=112). Of these, 69% of patients who received anifrolumab (177/257) and 46% of patients who received placebo (52/112) completed a total of 4 years on treatment. At Week 208, the mean SLEDAI- 2K score (SE) was 3.4 (0.25) and 4.0 (0.46) in patients who received anifrolumab (n=140) and placebo (n=44) respectively. The overall long-term safety profile of anifrolumab was consistent with the 52 week trials. For more information, please refer to the Summary of |
| PSUSA/10980 /202301 | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/08/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0010           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/07/2023 | 16/05/2024 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IA/0008             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/03/2023   | n/a   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10980 /202207 | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/03/2023   | n/a   | PRAC Recommendation - maintenance |
| IB/0005             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/12/2022   | n/a   |                                   |
| IA/0006/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 19/12/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| N/0004   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 18/10/2022   | 16/05/2024   | PL   |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|
| IB/0002  | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 05/05/2022   | n/a          |      |
| IB/0001  | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation           | 11/04/2022   | n/a          |      |